The method of treatment of neuropsychiatric disorders

 

The invention relates to medicine, namely to pharmacology and psychiatry. The patient with a neuropsychiatric disorder is administered a pharmaceutical composition comprising a therapeutically effective amount of the agonist glycine site on the NMDA receptor, in which the agonist is selected from the group consisting of D-alanine, a salt of D-alanine, a complex ester of D-alanine, alkylated D-alanine, a precursor of D-alanine, D-serine, salts of D-serine, a complex ester of D-serine, alkylated D-serine, a precursor of D-serine, D-cycloserine, a salt of D-cycloserine, a complex ester of D-cycloserine, predecessor of D-cycloserine and alkylated D-cycloserine. This pharmaceutical composition does not contain D-cycloserine, when the agonist is a D-alanine, a salt of D-alanine, an ester of D-alanine, alkilirovanny D-alanine, or a precursor of D-alanine, and when the agonist is a D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, a precursor of D-cycloserine or alkilirovanny D-cycloserine. The pharmaceutical composition comprises an amount of the agonist, equivalent 105-500 mg of D-cycloserine. The method allows to increase the effectiveness of the treatment. 3 c. and 43 C.p. f-crystals, 1 table.

<>p>

1. A method of treating neuropsychiatric disorders, comprising the administration to a patient diagnosed with a neuropsychiatric disorder a therapeutically effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of D-alanine, a salt of D-alanine, a complex ester of D-alanine, alkylated D-alanine, a precursor of D-alanine, D-serine, salts of D-serine, a complex ester of D-serine, alkylated D-serine, a precursor of D-serine, D-cycloserine, a salt of D-cycloserine, a complex ester of D-cycloserine, predecessor of D-cycloserine and alkylated D-cycloserine, where neuropsychiatric disorder is a schizophrenia, Alzheimer's disease, autism, depression, benign forgetfulness, learning disorder in childhood, the disorder with attention deficit and closed head injury, and when the drug is a D-alanine, a salt of D-alanine, an ester of D-alanine, alkilirovanny D-alanine, or a precursor of D-alanine, the pharmaceutical composition essentially contains no D-cycloserine and

when the drug is a D-cycloserine, a salt of D-cycloserine, an ester of D-cyclase icesto medicines equivalent 105-500 mg of D-cycloserine.

2. The method according to p. 1 wherein the neuropsychiatric disorder is a schizophrenic.

3. The method according to p. 1 wherein the neuropsychiatric disorder is a disease of Alzheimer's.

4. The method according to p. 1 wherein the neuropsychiatric disorder is an autism.

5. The method according to p. 1 wherein the neuropsychiatric disorder is a depression.

6. The method according to p. 1 wherein the neuropsychiatric disorder is a benign forgetfulness.

7. The method according to p. 1 wherein the neuropsychiatric disorder is a learning disorder in childhood.

8. The method according to p. 1 wherein the neuropsychiatric disorder is a disorder with attention deficit.

9. The method according to p. 1 wherein the neuropsychiatric disorder is a closed head injury.

10. The method according to p. 1, in which the drug is selected from the group consisting of D-alanine, a salt of D-alanine, a complex ester of D-alanine, alkylated D-alanine and predecessor of D-alanine.

11. The method according to p. 10, in which D-alanine, a salt of D-alanine, an ester of D-alanine, alkilirovanny D-alanine or preceded by carstone tool is a salt of D-alanine, selected from the group consisting of sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, and ammonium salt of D-alanine.

13. The method according to p. 10, in which the drug is an ester of D-alanine having the ester group with 1-20 carbon atoms.

14. The method according to p. 10, in which the drug is alkilirovanny D-alanine having alkyl group with 1-20 carbon atoms.

15. The method according to p. 10, in which the pharmaceutical composition also includes D-serine.

16. The method according to p. 1, in which the drug is selected from the group consisting of D-serine, and salts of D-serine.

17. The method according to p. 16, in which D-serine or a salt of D-serine is introduced at a dose equivalent to 10 mg to 100 g of D-serine.

18. The method according to p. 16, in which the drug is a salt of D-serine, selected from the group consisting of sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, and ammonium salt of D-serine.

19. The method according to p. 1, in which the drug is selected from the group consisting of a complex ester of D-serine, alkylated D-serine and precursor of D-serine.

20. The method according to p. 19, in which an ester of D-serine, a precursor of D-serine which the drug is an ester of D-serine, having ester group with 1-20 carbon atoms.

22. The method according to p. 1, in which the drug is alkilirovanny D-serine having alkyl group with 1-20 carbon atoms.

23. The method according to p. 1, in which the drug is selected from the group consisting of D-cycloserine, a salt of D-cycloserine, a complex ester of D-cycloserine, a predecessor of D-cycloserine and alkylated D-cycloserine.

24. The method according to p. 23, in which D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, alkilirovanny D-cycloserine or a precursor of D-cycloserine is introduced at a dose equivalent to 125-400 mg of D-cycloserine.

25. The method according to p. 24, in which D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, alkilirovanny D-cycloserine or a precursor of D-cycloserine is introduced at a dose equivalent to 150-300 mg of D-cycloserine.

26. The method according to p. 23, in which the pharmaceutical composition includes a salt of D-cycloserine selected from the group consisting of sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, and ammonium salt of D-cycloserine.

27. The method according to p. 23, which pharmaceutical composition comprises an ester of D-cycloserine, having ester group with 1-20 carbon atoms.

28. The method according to p. atomapi carbon.

29. The method according to p. 23, in which the pharmaceutical composition comprises a precursor of D-cycloserine.

30. The method according to p. 1, in which the drug is a D-serine.

31. The method according to p. 30, in which D-serine is introduced in a dose of 100 mcg - 100,

32. The method according to p. 30, in which D-serine is introduced at a dose of 1 mg to 100 mg

33. The method according to p. 30, in which D-serine is introduced in a dose of 10 mg - 10,

34. The method according to p. 30, in which D-serine is introduced at a dose of 10-500 mg.

35. The method according to p. 1, in which the pharmaceutical composition is administered to the patient at least once a day for at least one week.

36. The method according to p. 1 comprising, in addition, the introduction of the patient at least one drug selected from the group consisting of means for the treatment of psychosis, antidepressants, stimulants and drugs for the treatment of Alzheimer's disease.

37. Pharmaceutical composition comprising (i) a first drug selected from the group consisting of D-alanine, a salt of D-alanine, a complex ester of D-alanine, alkylated D-alanine, a precursor of D-alanine, D-serine, salts of D-serine, a complex ester of D-serine, alkylated D-serine, a precursor of D-serine, D-cycloserine, salts of D-cycloserine is arctonoe means, selected from the group consisting of means for the treatment of psychosis, antidepressants, stimulants and drugs for the treatment of Alzheimer's disease, and when the first drug is a D-alanine, a salt of D-alanine, an ester of D-alanine, alkilirovanny D-alanine, or a precursor of D-alanine, the pharmaceutical composition essentially contains no D-cycloserine and

when the first drug is a D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, a precursor of D-cycloserine or alkilirovanny D-cycloserine, a pharmaceutical composition includes a quantity of a drug equivalent to 105-500 mg of D-cycloserine.

38. The pharmaceutical composition according to p. 37, where the second drug is a medicine for the treatment of psychosis, selected from the group consisting of the typical tools for the treatment of psychosis, atypical funds for the treatment of psychosis and means for the treatment of psychosis prolonged action.

39. The pharmaceutical composition according to p. 37, where the second drug selected from the group consisting of chlorpromazine, thioridazine, mezoridazina, fluphenazine, perphenazine, triptocaine, Miotics is the fluphenazine decanoate, fluphenazine enanthate, amitriptyline, amoxapine, bupropion, bupropion SR, clomipramine, desipramine, doxepin, fluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, venlafaxine, venlafaxine XR, dextroamphetamine, methamphetamine, methylphenidate, pemoline, donepezil, tacrine, acetophenazine, chlorprothixene, droperidola, pimozida, butaperazine, terfenadine, remoxipride, piperacetazine, sulpiride and ziprasidone.

40. A method of treating schizophrenia, where the method comprises the administration to a patient who has been diagnosed with having schizophrenia, a therapeutically effective amount of D-serine.

41. The method according to p. 40, in which D-serine is introduced in a dose of 100 mcg - 100,

42. The method according to p. 40, in which D-serine is introduced at a dose of 1 mg to 100 mg

43. The method according to p. 40, in which D-serine is introduced in a dose of 10 mg to 100 g

44. The method according to p. 40, in which D-serine is introduced in a dose of 10 mg - 10,

45. The method according to p. 40, in which D-serine is introduced at a dose of 10-500 mg.

46. The method according to p. 2 in which treatment are positive symptoms of schizophrenia.

 

Same patents:

The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc

The invention relates to a new one with selective affinity to T6receptors, pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]triazines General formula I, where X denotes a =C(R4)- or =N-, R1denotes phenyl, optionally substituted by one or more radicals of lower alkyl, halogen, lower alkoxygroup, tolyl, pyridyl, naphthyl or thiophenyl, R2denotes hydrogen, (ness.)alkyl, (ness.)thioalkyl or hydroxy(ness.) alkoxygroup, R3denotes amino(ness.)alkylamino, di(ness.)alkylamino, piperazinil, optionally substituted by one or more radicals, lower alkyl, benzyl, phenyl or hydroxy(NISS

The invention relates to medicine and can be used to prevent degeneration of nerve cells and accelerate the regeneration of nerve cells

The invention relates to medicine, namely to homeopathic, treatment and prevention tools for internal and external use, has tonic, anti-inflammatory, wound healing, detoxifying, anti-microbial, antianginal, anti-atherosclerotic, antioxidant, antihypoxic, neuroprotective, sedative, cardioprotective, anti-arrhythmic, angioprotective, stress-protective, immunotropic, antifungal, nephroprotective, hepatoprotective, gastroprotective, thermoprotector, lipoic, megaproducer, radioprotective, and retinoprotective anticoordination action

The invention relates to new Amida formula (1) (R1)(R2)-X-Y-Q-R3(1) where R1and R2taken together, constitute butylen or penttinen, each of which may be condensed with benzene, optionally substituted C1-C6alkoxy; R3represents phenyl, substituted with halogen, X represents CH, Y represents-NH - and Q is-C(O)-, provided that when R1and R2taken together, constitute butylen condensed with benzene, then indan ring formed when taking together R1, R2and S, substituted in position 2 by a group - Y-Q-R3and their salts

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used as an aid in facilitating the normalization of peripheral (capillary) blood circulation, including brain

The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc

The invention relates to a new one with selective affinity to T6receptors, pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]triazines General formula I, where X denotes a =C(R4)- or =N-, R1denotes phenyl, optionally substituted by one or more radicals of lower alkyl, halogen, lower alkoxygroup, tolyl, pyridyl, naphthyl or thiophenyl, R2denotes hydrogen, (ness.)alkyl, (ness.)thioalkyl or hydroxy(ness.) alkoxygroup, R3denotes amino(ness.)alkylamino, di(ness.)alkylamino, piperazinil, optionally substituted by one or more radicals, lower alkyl, benzyl, phenyl or hydroxy(NISS

The invention relates to new Amida formula (1) (R1)(R2)-X-Y-Q-R3(1) where R1and R2taken together, constitute butylen or penttinen, each of which may be condensed with benzene, optionally substituted C1-C6alkoxy; R3represents phenyl, substituted with halogen, X represents CH, Y represents-NH - and Q is-C(O)-, provided that when R1and R2taken together, constitute butylen condensed with benzene, then indan ring formed when taking together R1, R2and S, substituted in position 2 by a group - Y-Q-R3and their salts

The invention relates to new substituted derivatives of piperidine derivatives, to processes for their preparation, to pharmaceutical compositions and to their use in medical therapy, particularly in treatment of psychotic disorders

The invention relates to thiophene derivative of the formula I, in which Ra and Rb may be the same or different and mean hydrogen, alkyl, acyl, alkenyl, phenyl, or Ra and Rb together may form a benzene ring or cyclohexanone ring, its pharmaceutically acceptable salts and hydrates

The invention relates to medicine, namely to methods and pharmaceutical compositions for stimulating the growth of neuritis in nerve cells containing neurotrophic amount of a compound that binds to FK-506-binding protein (FKBP), and neurotrophic factors such as nerve growth factor
The invention relates to medicine, namely to psychiatry

The invention relates to new derivatives of 1,2,3,4-tetrahydronaphthalene formula (I) as (R)-enantiomers, (S)-enantiomers or racemates, in the form of free base or pharmaceutically acceptable salt or solvate, where X is N or CH; Y is NR2-CH2, NR2-CO or CO-NR2; R2represents N or C1-C6-alkyl; R1represents N or C1-C6-alkyl; R3represents phenyl which may be mono - or Disaese4; R4represents H, halogen, CN, CF3WITH1-C6-alkoxy, optionally substituted heterocyclic ring containing one or two heteroatoms selected from N, O, or COR8; R8represents a heterocyclic ring containing one or two heteroatoms selected from N, O; R9is1-C6-alkyl, ОСНF2HE, halogen, C1-C6-alkoxy, C1-C6-alkoxy - C1-C6-alkyl

The invention relates to agriculture, namely, veterinary helminthology, and can be used to treat animals nematodosis
Up!